Evidence map›Paper›PMID 42514882›Full record

ArticlePharmaceutics2026

Desmocollin-3 Is a Novel Target Receptor for Targeted Drug Delivery for Malignant Prostate Cancer.

Vipin Sharma, Bharat Lohiya, Hanni Grace Francis, Galia Luboshits, Dror Tobi, Michael A Firer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vipin SharmaLaboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel.
Bharat LohiyaLaboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel.
Hanni Grace FrancisLaboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel.
Galia LuboshitsLaboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel.ORCID 0000-0002-3977-3989
Dror TobiDepartment of Molecular Biology, Ariel University, Ariel 40700, Israel.ORCID 0000-0002-1125-2751
Michael A FirerLaboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel.ORCID 0000-0002-8430-0486

Funding

Ariel University 2025/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

desmocollin-3peptide–drug conjugatesphage displayprostate cancertargeted drug delivery

Identifiers

PMID42514882
PMCPMC13415596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.